HomeAI · summaries
Storia in 2 fonti
Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC
The EMA's CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories’ Braftovi to treat mCRC with BRAFV600E mutations.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
pharmaceutical-technology.com
Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC
The EMA's CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories’ Braftovi to treat mCRC with BRAFV600E mutations.
- ·
adnkronos.com
Pierre Fabre Laboratories riceve il parere positivo del CHMP per BRAFTOVI® (encorafenib) in combinazione con cetuximab e FOLFOX…
CASTRES, Francia, 26 maggio 2026 /PRNewswire/ -- Pierre Fabre Laboratories ha annunciato oggi che il Comitato per i medicinali per uso umano (Committee for Medicinal Products for…